What is the recommended dosing of spironolactone (Aldactone)?

Spironolactone (Aldactone) Dosing

For heart failure with reduced ejection fraction, initiate spironolactone at 25 mg once daily in standard-risk patients (eGFR >50 mL/min/1.73 m², potassium ≤5.0 mEq/L, creatinine ≤1.6 mg/dL), or 12.5 mg daily (or every other day) in high-risk patients with renal impairment, advanced age, or borderline hyperkalemia, then titrate to a target maintenance dose of 50 mg daily after 4-8 weeks if tolerated. 1, 2

Heart Failure Dosing Algorithm

Pre-Initiation Requirements

• Serum potassium must be ≤5.0 mEq/L before starting therapy 1, 2
• eGFR must be >30 mL/min/1.73 m²; spironolactone is contraindicated below this threshold 1, 2
• Discontinue or reduce potassium supplements prior to initiation 1, 3
• Counsel patients to avoid potassium-rich foods and salt substitutes 1, 4

Initial Dose Selection

Standard-Risk Patients (start 25 mg daily): 1, 2

• eGFR >50 mL/min/1.73 m²
• Serum potassium ≤4.5 mEq/L
• Creatinine ≤1.6 mg/dL
• Age <75 years

High-Risk Patients (start 12.5 mg daily or every other day): 1, 3, 2

• eGFR 30-50 mL/min/1.73 m²
• Serum potassium 4.5-5.0 mEq/L
• Creatinine >1.6 mg/dL
• Age ≥75 years
• Insulin-requiring diabetes
• Concurrent high-dose ACE inhibitor or ARB

The FDA label explicitly recommends considering 25 mg every other day for patients with eGFR 30-50 mL/min/1.73 m² due to hyperkalemia risk. 2

Dose Titration

• Increase to target dose of 50 mg daily after 4-8 weeks if patient tolerates initial dose without hyperkalemia or renal deterioration 1, 3
• If hyperkalemia develops on 25 mg daily, reduce to 25 mg every other day 2
• The 2022 ACC/AHA guideline emphasizes maintaining target doses long-term even if symptoms improve 1

Monitoring Protocol

Early Monitoring (Critical Period)

• Check potassium and creatinine on day 3 after first dose 1, 3
• Recheck at day 7 1, 3
• Additional checks at weeks 1,2,3, and 4 3, 4

This intensive early monitoring is essential because real-world hyperkalemia rates reach 13-24% in the first weeks—far exceeding the 2% seen in controlled trials. 1, 3

Long-Term Monitoring

• Monthly for first 3 months, then every 3-6 months thereafter 1, 4
• Restart intensive monitoring cycle when adding or increasing ACE inhibitors or ARBs 1

Hyperkalemia Management

Potassium 5.5-5.9 mEq/L: 1, 3

• Halve the spironolactone dose (e.g., 25 mg to 12.5 mg daily or switch to alternate-day dosing)
• Recheck potassium within 3 days
• Stop potassium supplementation if still prescribed

Potassium ≥6.0 mEq/L: 1, 3

• Discontinue spironolactone immediately
• Initiate emergency hyperkalemia treatment
• Monitor electrolytes closely

The 2022 ACC/AHA guideline states that MRA should be discontinued when potassium cannot be maintained <5.5 mEq/L to avoid life-threatening hyperkalemia. 1

Other Indications

Hypertension

• Initial dose: 25-100 mg daily in single or divided doses 2
• Titrate at 2-week intervals
• Doses >100 mg/day provide no additional blood pressure reduction 2, 5

Cirrhotic Ascites

• Initial dose: 100 mg daily (range 25-200 mg) in single or divided doses 2
• Initiate in hospital setting and titrate slowly 2
• Maximum dose 400 mg daily for refractory cases 6
• Administer for at least 5 days before increasing dose 2

Primary Hyperaldosteronism

• Dose: 100-400 mg daily for preoperative preparation or long-term maintenance 2, 7

Critical Safety Considerations

Absolute Contraindications 2

• Hyperkalemia (potassium >5.0 mEq/L at baseline)
• eGFR <30 mL/min/1.73 m²
• Addison's disease
• Concomitant eplerenone use

Drug Interactions to Avoid

• NSAIDs and COX-2 inhibitors cause worsening renal function and precipitate hyperkalemia 1, 3
• Triple therapy (ACE inhibitor + ARB + spironolactone) is not recommended due to severe hyperkalemia risk 1, 3

Common Pitfalls

• Initiating 25 mg in elderly patients or those with eGFR 30-50 mL/min/1.73 m² without dose reduction is a frequent and dangerous error 3
• Delaying the day-3 potassium check is critical oversight; the first week carries highest risk for life-threatening hyperkalemia 3
• Failure to verify baseline electrolytes and renal function before starting can lead to serious adverse effects 4
• Volume depletion from gastroenteritis or other causes markedly increases hyperkalemia risk 1, 3

Adverse Effects

Gynecomastia

• Occurs in approximately 10% of men, dose-dependent 6, 2
• Onset varies from 1-2 months to over a year 2
• Usually reversible upon discontinuation 2
• Consider switching to eplerenone if gynecomastia becomes problematic 1, 6, 3

Other Anti-Androgenic Effects

• Decreased libido and erectile dysfunction can occur 6
• Not seen with eplerenone 1

Evidence Quality Note

The 2022 ACC/AHA guideline supersedes the 2005 version and provides updated Class I, Level A recommendations for MRA use in heart failure, emphasizing the high economic value of this therapy. 1 The FDA label aligns with these recommendations for heart failure dosing. 2 Research from TOPCAT suggests that even lower-than-target doses (median ~20 mg/day) remain efficacious in high-risk subgroups, and discontinuation is associated with 2-4 fold higher risk of subsequent events. 8